HormonalFDA Approved
Lanreotide
Somatuline
A somatostatin analog that binds preferentially to SST2 and SST5 receptors for treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors.
FDA Approved60-120 mg every 4 weeks
Peptide Database
Browse Research Peptides
Comprehensive profiles for 105+ peptides — dosing protocols, mechanisms of action, clinical research, and safety data.
105
Peptides
9
Categories
105 peptides · page 3 of 5
HormonalFDA Approved
Leuprolide
Lupron
A GnRH agonist suppressing testosterone and estrogen production, approved for prostate cancer, endometriosis, uterine fibroids, and precocious puberty.
FDA Approved7.5 mg monthly depot (common)
HormonalFDA Approved
Linaclotide
Linzess
A peptide activator of guanylate cyclase-C for irritable bowel syndrome with constipation and chronic idiopathic constipation, with localized gut action and minimal systemic uptake.
FDA Approved290 mcg daily (IBS-C) or 145 mcg daily (CIC)
Weight LossFDA Approved
Liraglutide
Victoza
An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing. 97% homology to native GLP-1.
FDA Approved1.8-3 mg daily
BioregulatorPreclinical
Livagen
Lys-Glu-Asp-Ala
A tetrapeptide bioregulator (Lys-Glu-Asp-Ala) developed by Khavinson that modulates chromatin structure. Studies in elderly subjects (75-88 years) showed activation of ribosomal genes.
Animal Studies10-20 mg daily
Growth HormoneIn Clinical Trials
MK-677
Ibutamoren
An orally active growth hormone secretagogue that mimics ghrelin. Provides 24-hour GH elevation due to long half-life.
Clinical Trials10-25 mg daily
HormonalPreclinical
MOTS-c
Mitochondrial ORF of the 12S rRNA type-c
A mitochondria-derived peptide that regulates metabolic homeostasis, discovered in 2015 and studied for insulin sensitivity, exercise capacity, and aging effects.
Animal Studies5-10 mg weekly
HormonalFDA Approved
Macimorelin
Macrilen
An oral ghrelin mimetic for diagnosing adult growth hormone deficiency. The first FDA-approved oral GH stimulation test. 92% concordance with insulin tolerance testing.
FDA Approved0.5 mg/kg oral single dose
Skin & HairNot FDA Approved
Matrixyl
Palmitoyl Pentapeptide-4
A lipopeptide that signals to fibroblasts to produce more collagen and other extracellular matrix proteins. Studies show significant reduction in wrinkle depth and volume.
Community3-8% in formulations
Skin & HairNot FDA Approved
Matrixyl 3000
Palmitoyl Tripeptide-1
A combination of Pal-GHK (collagen synthesis) and Pal-GQPR (anti-inflammatory) for superior anti-aging effects. Studies show superior wrinkle reduction versus original Matrixyl.
Community2-8% in formulations
Skin & HairFDA Approved
Melanotan I
Afamelanotide
A 13-amino acid synthetic analog of α-MSH that stimulates melanin production. FDA approved for erythropoietic protoporphyria. Unlike MT-II, minimal affinity for MC3R and MC4R.
FDA Approved500-1000 mcg daily (loading), 500-1000 mcg 1-2x weekly (maintenance)
HormonalNot FDA Approved
Melanotan II
MT-II
A synthetic analog of alpha-melanocyte stimulating hormone (α-MSH). Known for inducing skin tanning and having effects on libido and sexual function.
Community250-500 mcg daily (loading), 500-1,000 mcg weekly (maintenance)
Anti-AgingIn Clinical Trials
NAD+ Precursors
NMN
While not peptides, NAD+ precursors are frequently discussed alongside peptides in longevity circles. They boost cellular NAD+ levels, supporting energy metabolism and sirtuin activity.
Clinical TrialsNMN: 250-1000mg daily; NR: 300-1000mg daily
CognitiveNot FDA Approved
Normoftal
Eye Peptide Bioregulator
Synthesized Khavinson peptide bioregulator containing short peptides (2-4 amino acids) derived from retinal tissue. 1,500 patients treated from 1995-2010 with 95% showing improved visual functions.
Clinical Trials20-40 mg daily (therapy); 20 mg daily (prevention)
HormonalFDA Approved
Octreotide
Sandostatin
A somatostatin analog that binds to SST2 and SST5 receptors, suppressing GH, glucagon, insulin, and gastrointestinal hormones.
FDA Approved100-500 mcg SC 2-3x daily or LAR monthly
Weight LossNot FDA Approved
Orforglipron
LY3502970
An oral non-peptide GLP-1 receptor agonist. First oral GLP-1 agonist not requiring food restrictions.
Clinical Trials12-45 mg once daily
BioregulatorPreclinical
Ovagen
Glu-Asp-Leu
A tripeptide bioregulator targeting liver and gastrointestinal tissue, derived from liver tissue extracts. Modulates gene expression related to detoxification, antioxidant defense, and cellular repair.
Animal Studies10-20 mg daily
HormonalFDA Approved
Oxytocin
Pitocin
A naturally occurring peptide hormone essential for social bonding, childbirth, and lactation. Under investigation for autism, anxiety, and social disorders.
FDA Approved10-24 IU intranasal as needed
CognitivePreclinical
P21
P021
A synthetic peptide mimetic of CNTF (ciliary neurotrophic factor) designed for neurodegenerative disease. Promotes neurogenesis and reduces neuroinflammation.
Animal Studies10-15 mg daily
CognitivePreclinical
PE-22-28
PE22-28
A synthetic heptapeptide (7 amino acids) derived from Spadin, a naturally occurring antidepressant peptide, with enhanced stability.
Animal Studies100-300 mcg intranasal or subcutaneous
ImmunePreclinical
PNC27
PNC-27
A peptide containing p53 binding domain (residues 12-26) fused to membrane-penetrating peptide. Selectively targets cancer cells expressing HDM-2 on plasma membranes.
Animal StudiesNo human dose established - research compound only
HormonalFDA Approved
PT-141
Bremelanotide
An FDA-approved melanocortin receptor agonist for treating hypoactive sexual desire disorder (HSDD) in premenopausal women.
FDA Approved1.75 mg as needed
BioregulatorNot FDA Approved
Pancragen
KEDW Tetrapeptide
Synthetic tetrapeptide bioregulator originally isolated from bovine pancreatic cells, developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology.
Clinical Trials1-2 capsules (10-20 mg) daily
HormonalFDA Approved
Pasireotide
Signifor
A somatostatin analog with broader receptor binding than octreotide, particularly effective for Cushing's disease due to SST5 receptor activity.
FDA Approved300-900 mcg twice daily (SC) or 40-60 mg monthly (LAR)